Organ Transplant Rejection Medication Market Size & Share 2023 to 2032
Market Size by Drug Class (Calcineurin Inhibitor, Antibodies, Antiproliferative Agent), Transplant Type (Kidney, Liver, Heart), Distribution Channel (Hospital, Retail Pharmacies), Global Forecast.
Report ID: GMI6581
|
Published Date: August 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Organ Transplant Rejection Medication Market Size
Organ Transplant Rejection Medication Market size in 2022 was valued at USD 5.5 billion and is expected to witness growth at CAGR of 3.2% and reach USD 7.5 billion by 2032. The factors driving the growth of global organ transplant rejection medication includes increasing organ transplant procedures due to chronic diseases and technological advancements in organ transplantation and tissue engineering.
Organ Transplant Rejection Medication Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Organ transplant rejection refers to the immune response of a recipient's body against a transplanted organ or tissue, considering it as foreign and attempting to destroy it. The organ transplant rejection medications also known as immunosuppressive medications or immunosuppressants, are drugs used to suppress this immune response and allow the transplanted organ to function properly within the recipient's body.
COVID-19 Impact
Due to the pandemic, many hospitals and healthcare facilities faced challenges and had to reallocate resources and prioritize COVID-19 patients. This resulted in the reduction of non-essential medical procedures, including transplant diagnostics and organ transplantation. The challenges in organ procurement, transportation, and availability, causing delays and cancellations of transplant surgeries were majorly experienced. The global supply chain disruptions had a significant impact on the availability of pharmaceutical ingredients, packaging materials, and finished products which had led to the shortages or delays in obtaining necessary medications. To prevent organ rejection, the transplant recipients require careful monitoring and management of immunosuppressive medications. The pandemic disrupted routine medical appointments, due to utilization and prioritization of medical facilities for treating covid-19 patients, leading to potential challenges in medication management and adherence.
Organ Transplant Rejection Medication Market Driving & Restraining Factors
The increasing organ transplant procedures due to chronic diseases and technological advancements in organ transplantation and tissue engineering are the major factors driving the growth of the global market. The increasing prevalence of end-stage organ diseases and improved patient outcomes have increased the demand of organ transplant procedures. Due to the increasing number of transplants the demand for rejection medications is also growing.
The restraining factors of the global market are high cost of organ transplantation procedures and low availability of organs for transplantation. The cost of organ transplantation procedures is high, and the lifelong use of immunosuppressive medications can result in significant financial burden on patients.
Organ Transplant Rejection Medication Market Analysis
Based on drug class, the organ transplant rejection medicine market is segmented into calcineurin inhibitors, antibodies, antiproliferative agents, mTOR inhibitor, and steroids. In 2022, the calcineurin inhibitors accounted for significant market share of 35.7% due to high prescription rate of the drugs Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine) which belongs to this class. They help in preventing acute rejection episodes that can lead to organ dysfunction and failure if left untreated. In addition to this, these inhibitors are suitable for long-term use and can be used for post-transplant maintenance therapy. They are available in various forms, including oral formulations and intravenous preparations allowing flexibility in administration.
Based on transplant type, the organ transplant rejection medicine market is classified into kidney, liver, heart, lung, pancreas, and other transplant types. The kidney segment is expected to grow at CAGR of 3.3% during the forecast period. Kidneys are highly immunogenic organs to which immune systems are more likely to recognize and respond to them as foreign. This can result in a stronger immune response and a higher risk of rejection. Additionally, the number of patients with kidney transplant are increasing globally. For, instance, United Network of Organ Sharing, on an average, 68 people received a new kidney each day in 2021. Kidney transplants are more cost-effective compared to dialysis and people with kidney failure gets an opportunity to live without extended period of dialysis.
Based on the distribution channel, the organ transplant rejection medicine market is segmented into hospital, retail, and online pharmacies. The hospital pharmacies segment held highest market share of 61.6%. Hospital pharmacies are commonly used for dispensing and managing organ transplant rejection medications. The hospital pharmacies offer easy and rapid access to such medications for the hospitalized patients. The retail pharmacies accounted for second highest market share due to the availability of various organ transplant rejection medications, whereas the online pharmacies segment is expected to grow at fastest growth rate due to convenience and accessibility of purchasing such medicines.
The North America organ transplant rejection medicine market was valued to be USD 2.4 billion in 2022. The well-developed healthcare systems, advanced healthcare infrastructure, increasing healthcare expenditure, increasing prevalence of chronic diseases, increasing research and development, and presence of key players operating are some of the factors boosting the growth of this market. During the forecast period, Asia Pacific organ transplant rejection market is expected to grow due to the increasing number of organ transplant, increasing prevalence of chronic diseases, increased research and development of novel immunosupppressants, and expansion of key players.
Organ Transplant Rejection Medication Market Share
The key players in the organ transplant rejection medicine market are
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
Organ Transplant Rejection Medication Industry News:
The organ transplant rejection medication market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
Market Size, By Drug Class
Market Size, By Transplant Type
Market Size, By Distribution Channel
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →